HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effective treatment of adult T cell leukemia/lymphoma with a novel oral antitumor agent, MST-16.

Abstract
Adult T cell leukemia/lymphoma (ATLL) induced by human T cell leukemia virus I is resistant to conventional therapy. Six patients with ATLL were treated with a new antitumor agent, MST-16, which is a derivative of bis(2,6-dioxopiperazine). Two patients achieved complete remission, lasting 12 months and more than 8 months, and 2 others partial remission, lasting 2 months and 6 weeks, respectively. The major toxicity was myelosuppression. Other toxicities were not severe and were well tolerable. Orally administered MST-16 is a promising agent for the treatment of ATLL.
AuthorsT Ichihashi, H Kiyoi, H Fukutani, K Kubo, T Yamauchi, T Naoe, K Yamada, R Ohno
JournalOncology (Oncology) Vol. 49 Issue 5 Pg. 333-5 ( 1992) ISSN: 0030-2414 [Print] Switzerland
PMID1528567 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Piperazines
  • sobuzoxane
Topics
  • Administration, Oral
  • Adult
  • Aged
  • Antineoplastic Agents (therapeutic use)
  • Drug Evaluation
  • Female
  • Humans
  • Leukemia-Lymphoma, Adult T-Cell (drug therapy)
  • Male
  • Piperazines (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: